News und Analysen
Form 8.3 - Maitland Institutional Services Limited: Re Diurnal Group plc
Form 8.3 - Maitland Institutional Services Limited: Re Diurnal Group plc
Uni-Bio Science Group Limited: 2022 Interim Results
Uni-Bio Science Group Limited: 2022 Interim Results
Relief Therapeutics files registration statement on form F-1 with the U.S. Securities and Exchange Commission
Relief Therapeutics files registration statement on form F-1 with the U.S. Securities and Exchange Commission
Pharnext Announces a €2.5m Loan Agreement with Néovacs
Pharnext Announces a €2.5m Loan Agreement with Néovacs
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. announce tentative settlement of pending litigation
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. announce tentative settlement of pending litigation
Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access
Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access
DGAP-News: Burcon Reports Fiscal 2023 First Quarter Results
DGAP-News: Burcon Reports Fiscal 2023 First Quarter Results
DGAP-News: Heidelberg Pharma AG Launches Rights Issue of up to EUR 80 Million
DGAP-News: Heidelberg Pharma AG Launches Rights Issue of up to EUR 80 Million
Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease
Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease
DGAP-News: Burcon Announces Fiscal 2023 First Quarter Conference Call to be Held on August 15, 2022
DGAP-News: Burcon Announces Fiscal 2023 First Quarter Conference Call to be Held on August 15, 2022
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100® (Aviptadil)
Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100® (Aviptadil)
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O
DGAP-News: Burcon JV, Merit Functional Foods Achieves Significant Innovation in a 100% Protein-based Solution to Replace Methylcellulose in Meat Alternatives
DGAP-News: Burcon JV, Merit Functional Foods Achieves Significant Innovation in a 100% Protein-based Solution to Replace Methylcellulose in Meat Alternatives
Valbiotis meldet den Abschluss der Rekrutierung für die klinische Phase II/III-Studie REVERSE-IT mit TOTUM•63 gegen Prädiabetes in Partnerschaft mit Nestlé Health Science
Valbiotis (FR0013254851 - ALVAL, PEA/KMU-qualifiziert) (Paris:ALVAL), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
Valbiotis Announces Completion of Recruitment for the Phase II/III REVERSE-IT Clinical Study With TOTUM•63 Against Prediabetes, in Partnership With Nestlé Health Science
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
DGAP-News: Burcon to Present at the Canaccord Genuity 42nd Annual Growth Conference
DGAP-News: Burcon to Present at the Canaccord Genuity 42nd Annual Growth Conference
DGAP-News: Burcon NutraScience Corp.: Burcon JV, Merit Functional Foods Launches New Peazazz C Pea Protein Ingredient
DGAP-News: Burcon NutraScience Corp.: Burcon JV, Merit Functional Foods Launches New Peazazz C Pea Protein Ingredient
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F
Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F
Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (sodium phenylbutyrate) New Drug Application (NDA) to the FDA for the treatment of urea cycle disorders (UCDs)
Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (sodium phenylbutyrate) New Drug Application (NDA) to the FDA for the treatment of urea cycle disorders (UCDs)
Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine
Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine
DGAP-Adhoc: Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate
DGAP-Adhoc: Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate
Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU
Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU